丙酚替諾福韋

**丙酚替諾福韋**
臨床資料
讀音	/ˌtəˈnoʊfəvɪər ˌæləˈfɛnəmaɪd/
商品名（英語：Drug nomenclature）	韋立德（Vemlidy）
其他名稱	GS-7340
AHFS/Drugs.com	Monograph
核准狀況	歐 EMA: yes; 美 DailyMed: Tenofovir_alafenamide;
懷孕分級	澳: B3 ; ;
給藥途徑	口服
ATC碼	J05AF13 (WHO) Combination codes: J05AR17 J05AR18 J05AR19 J05AR20 J05AR22;
法律規範狀態
法律規範	中：處方藥 ; 歐：Rx-only; 英：處方藥（℞-only） (POM); 美：處方藥（℞-only）;
藥物動力學數據
血漿蛋白結合率	~80%
生物半衰期	33分鐘
排泄途徑	腸道排泄（31.7%）和腎臟排泄（<1%）
識別資訊
	IUPAC命名法 Isopropyl (2S)-2-[[[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]propanoate; ;
CAS號	379270-37-8
PubChem CID	9574768;
DrugBank	DB09299;
ChemSpider	7849225;
UNII	EL9943AG5J;
KEGG	D10428;
ChEBI	CHEBI:90926 ;
ChEMBL	ChEMBL2107825;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID50958941 ;
化學資訊
化學式	C21H29N6O5P
摩爾質量	476.47 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3;
	InChI InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1; Key:LDEKQSIMHVQZJK-CAQYMETFSA-N;

丙酚替諾福韋（Tenofovir alafenamide，縮寫TAF，商品名韋立德（Vemlidy））是一種口服抗逆轉錄病毒藥物，臨床上應用其延胡索酸鹽的形式（富馬酸丙酚替諾福韋) 用於治療B型肝炎或與其他藥物聯用治療愛滋病。

該藥為替諾福韋的前藥，由吉利德科學研發。與常用的逆轉錄酶抑制劑替諾福韋二吡呋酯（TDF）相比，丙酚替諾福韋具有更強的抗病毒活性和更好的淋巴組織分布。^[5]^[6]該藥於2016年11月獲得FDA批准上市。^[7]

參考文獻編輯

^ ^1.0 ^1.1 Tenofovir alafenamide (Vemlidy) Use During Pregnancy. Drugs.com. 26 December 2018 [18 April 2020]. （原始內容存檔於2021-07-09）.
^ Vemlidy 25 mg film coated tablets - Summary of Product Characteristics (SmPC). (emc). 8 September 2020 [12 November 2020]. （原始內容存檔於2021-07-11）.
^ ^3.0 ^3.1 Vemlidy- tenofovir alafenamide tablet. DailyMed. 11 February 2020 [18 April 2020]. （原始內容存檔於2021-07-09）.
^ Vemlidy EPAR. European Medicines Agency (EMA). [2021-07-01]. （原始內容存檔於2021-07-13）.
^ Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids. 2001, 20 (4–7): 1091–8. PMID 11562963. doi:10.1081/NCN-100002496.
^ M Markowitz, A Zolopa, et al.
^ FDA Approves Vemlidy (tenofovir alafenamide) for Chronic Hepatitis B in Adults. United States Department of Health and Human Services. 21 November 2016 [11 October 2019]. （原始內容存檔於11 October 2019）.
^ Descovy- emtricitabine and tenofovir alafenamide tablet. DailyMed. 13 January 2020 [18 April 2020]. （原始內容存檔於2021-06-24）.
^ FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. U.S. Food and Drug Administration (FDA). 3 October 2019 [11 October 2019]. （原始內容存檔於11 October 2019）.
^ Mandavilli, Apoorva. F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Everyone. The New York Times. 4 October 2019 [11 October 2019]. （原始內容存檔於2021-07-09）.
^ Symtuza- darunavir, cobicistat, emtricitabine, and tenofovir alafenamide tablet, film coated. DailyMed. 6 March 2020 [18 April 2020]. （原始內容存檔於2021-07-09）.
^ Drug Approval Package: Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide). U.S. Food and Drug Administration (FDA). 11 December 2018 [19 August 2020]. （原始內容存檔於2021-07-09）.
^ Symtuza EPAR. European Medicines Agency. [19 August 2020]. （原始內容存檔於2021-07-10）.
^ http://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=CCE11C6BC5177A30CA2585AE00423857&agid=(PrintDetailsPublic)&actionid=1^{[失效連結]}
^ Drugs@FDA: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [5 December 2020]. （原始內容存檔於2021-07-09）.

外部連結編輯

Tenofovir alafenamide. Drug Information Portal. U.S. National Library of Medicine. [2021-07-01]. （原始內容存檔於2021-06-24）.
Tenofovir alafenamide fumarate. Drug Information Portal. U.S. National Library of Medicine. [2021-07-01]. （原始內容存檔於2021-07-09）.

[Drugs.com_pregnancy-1] 1.0 ^1.1 Tenofovir alafenamide (Vemlidy) Use During Pregnancy. Drugs.com. 26 December 2018 [18 April 2020]. （原始內容存檔於2021-07-09）.

[2] Vemlidy 25 mg film coated tablets - Summary of Product Characteristics (SmPC). (emc). 8 September 2020 [12 November 2020]. （原始內容存檔於2021-07-11）.

[Vemlidy_FDA_label-3] 3.0 ^3.1 Vemlidy- tenofovir alafenamide tablet. DailyMed. 11 February 2020 [18 April 2020]. （原始內容存檔於2021-07-09）.

[Vemlidy_EPAR-4] Vemlidy EPAR. European Medicines Agency (EMA). [2021-07-01]. （原始內容存檔於2021-07-13）.

[5] Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids. 2001, 20 (4–7): 1091–8. PMID 11562963. doi:10.1081/NCN-100002496.

[6] M Markowitz, A Zolopa, et al.

[7] FDA Approves Vemlidy (tenofovir alafenamide) for Chronic Hepatitis B in Adults. United States Department of Health and Human Services. 21 November 2016 [11 October 2019]. （原始內容存檔於11 October 2019）.

[8] Descovy- emtricitabine and tenofovir alafenamide tablet. DailyMed. 13 January 2020 [18 April 2020]. （原始內容存檔於2021-06-24）.

[9] FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. U.S. Food and Drug Administration (FDA). 3 October 2019 [11 October 2019]. （原始內容存檔於11 October 2019）.

[10] Mandavilli, Apoorva. F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Everyone. The New York Times. 4 October 2019 [11 October 2019]. （原始內容存檔於2021-07-09）.

[11] Symtuza- darunavir, cobicistat, emtricitabine, and tenofovir alafenamide tablet, film coated. DailyMed. 6 March 2020 [18 April 2020]. （原始內容存檔於2021-07-09）.

[12] Drug Approval Package: Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide). U.S. Food and Drug Administration (FDA). 11 December 2018 [19 August 2020]. （原始內容存檔於2021-07-09）.

[13] Symtuza EPAR. European Medicines Agency. [19 August 2020]. （原始內容存檔於2021-07-10）.

[14] ttp://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=CCE11C6BC5177A30CA2585AE00423857&agid=(PrintDetailsPublic)&actionid=1^{[失效連結]}

[15] Drugs@FDA: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [5 December 2020]. （原始內容存檔於2021-07-09）.

[1]

[4]

[2]

[3]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

丙酚替諾福韋

相關複方藥物 編輯

參考文獻 編輯

外部連結 編輯

相關複方藥物編輯

參考文獻編輯

外部連結編輯